Lineage Cell Therapeutics :
Leading clinical-stage cell therapy company with in-house manufacturing capabilities and clinically validated technology. Innovative programs based on one of the largest and most comprehensive patent estates in cell therapy. 3 clinical programs in markets with billion dollar opportunities: 1) OpRegen, an RPE transplant therapy in Phase 1/2a development for the treatment of dry-AMD. Positive clinical results reported in first 16 enrolled patients, study expected to complete enrollment in Q1 2020 with an innovative delivery device from Orbit Biomedical Ltd.; 2) OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations. Positive clinical results reported from ongoing Phase 1/2a study for treatment of acute SCI. Program focus in 2020 are manufacturing enhancements and meeting with FDA to prepare for the next study; 3) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Phase 1 for NSCLC conducted by CRUK. Company is also evaluating partnership opportunities to commercialize Renevia, a proprietary 3-D scaffold designed to support adipose tissue transplant and retention and which received a CE Mark in September 2019 for use in adults for the treatment of facial lipoatrophy.
US - Pacific
100MM - 500MM
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501-1147
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of Lineage Cell Therapeutics, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by